Anupam Rasayan India Q4 FY26 Earnings Results: Total Income up 26.4% YoY and Plans to Acquire 74.2% of Bliss GVS Pharma

Anupam Rasayan India has announced its audited financial results for the quarter and year ending March 31, 2026. The company has also disclosed plans for a significant acquisition in the pharmaceutical sector. 

Anupam Rasayan India Q4 FY26 Earnings Results 

In the March 2026 quarter, Anupam Rasayan India's total income increased by 26.4% year-on-year to ₹639.15 crore, up from ₹505.70 crore in the same quarter the previous year.  

This also marked a 24.2% quarter-on-quarter rise from ₹514.55 crore in December 2025.  

However, the net profit for the March 2026 quarter decreased by 11.0% year-on-year to ₹56.00 crore, compared to ₹62.93 crore a year ago, and was down 7.6% quarter-on-quarter from ₹60.59 crore in December 2025. 

Annual Financial Highlights 

For the financial year 2025-26, Anupam Rasayan India reported a total income of ₹2,383.63 crore, reflecting a 64.6% increase from ₹1,448.45 crore in the previous year.  

The net profit for the year rose by 38.9% to ₹222.20 crore, up from ₹159.97 crore in the previous year.  

Dividend Announced 

The company has recommended a final dividend of ₹1.5 per equity share, representing 15% of the face value of ₹10 each, subject to approval at the upcoming 23rd Annual General Meeting. 

Acquisition of Bliss GVS Pharma 

In a strategic move, Anupam Rasayan India plans to acquire up to 74.20% of Bliss GVS Pharma Limited.  

This acquisition will involve the purchase of 4,58,03,024 equity shares, representing 43.30% of Bliss GVS Pharma's total paid-up share capital, at a price of ₹299 per share.  

Additionally, Anupam Rasayan India has the option to acquire the remaining shares held by the sellers, which could increase its stake to 74.20%. 

Read More: Allcargo Terminals Share Price In Focus; Acquires 25% Stake In Group Services Unit, Reallocates Rights Issue Proceeds! 

Open Offer to Public Shareholders 

Anupam Rasayan India will also make an open offer to acquire up to 26% of Bliss GVS Pharma's equity share capital from eligible public shareholders at ₹299 per share.  

This move is in compliance with the Securities and Exchange Board of India regulations. 

Anupam Rasayan India Share Price Performance 

As of May 25, 2026, at 11:14 AM, Anupam Rasayan India share price on NSE was trading at ₹1,357.00 down by 0.67% from the previous closing price. 

Conclusion 

Anupam Rasayan India's financial performance for the year ending March 31, 2026, reflects significant growth in total income and net profit. The proposed acquisition of Bliss GVS Pharma is expected to enhance the company's presence in the pharmaceutical sector. 

Want to track these market movements in Hindi? Visit Angel One News for daily updates and comprehensive share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.